Novavax, Inc. (NVAX) is an interesting player in the Healthcare space, with a focus on Biotechnology. The stock has been active on the tape, currently trading at $2.15, up from yesterday’s close by 0.00%. Given the stock’s recent action, it seemed like a good time to take a closer look at the company’s recent data.Fundamental Analysis
Novavax, Inc. (NVAX) currently trades with a market capitalization of $667.75 Million. That value represents a market adjusting for revenues that have been growing by 158.50 % on a quarterly year/year basis as of the company’s last quarterly report.
You can get a sense of how sustainable that is by a levered free cash flow of -$167.39 Million over the past twelve months. Generally speaking, earnings are expected to grow in coming quarters. Analysts are forecasting earnings of -$0.15 on a per share basis this quarter. Perhaps, that suggests something about why 0.81% of the outstanding share supply is held by institutional investors.
We’ve taken a serious look at this stock from a fundamental perspective, but the tale of the tape may offer more hints about what lies under the surface. Looking at the stock’s movement on the chart, Novavax, Inc. recorded a 52-week high of $2.75. It is now trading 0.6% off that level. The stock is trading $1.98 its 50-day moving average by -0.17%. The stock carved out a 52-week low down at $0.73.
In recent action, Novavax, Inc. (NVAX) has made a move of +6.97% over the past month, which has come on weak relative transaction volume. Over the trailing year, the stock is underperforming the S&P 500 by 16.68, and it’s gotten there by action that has been more volatile on a day-to-day basis than most other stocks on the exchange. In terms of the mechanics underlying that movement, traders will want to note that the stock is trading on a float of 15.72% with $309.38 Million sitting short, betting on future declines. That suggests something of the likelihood of a short squeeze in shares of NVAX.